Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Businessman carrying big bag of money moving forward

Venture capital

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

While venture capital funding dipped to a six-year low in 2025, it nevertheless remained above pre-pandemic levels for Massachusetts-based biopharma companies, according to MassBio.

January 8, 2026

2 min read

Tristan Manalac

Illustration of two hands shaking while another hand gently grips a wrist

Collaboration

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

The deals will help Lilly diversify its portfolio that is heavily weighted on the obesity juggernaut tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss.

January 8, 2026

2 min read

Tristan Manalac

Pictured: Office building science collage

Career Advice

The Top 12 Companies Hiring in Biopharma Now

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

January 8, 2026

1 min read

Chantal Dresner

Illustration of businesspeople with forward progress stopped because of chasm between them and arrow pointing forward

Layoffs

Biopharmas Axed 47% More Employees Year Over Year

In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to BioSpace tallies. BioSpace takes a deep dive into which companies and locations were impacted and speaks to experts about what to expect ahead—and why.

January 8, 2026

5 min read

Angela Gabriel

Focus on the path, Businessman running on his own track

Rare diseases

Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money

The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity.

January 7, 2026

2 min read

Dan Samorodnitsky

Mechanical heart in steampunk style.On a background of steel sheets. Vector illustration.

Startups

Corsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic

The cardiovascular biotech was also named as one of BioSpace’s top startups to watch on Wednesday.

January 7, 2026

1 min read

Annalee Armstrong

Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.

Infectious disease

GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

January 7, 2026

2 min read

Tristan Manalac

Achieve goal concept art collage. Rising arrow chart and halftone hand pointing to center of dartboard. Business goal, achieve targets, success. Trendy modern retro vector illustration

Stomach cancer

Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer

Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall survival signals ever reported in a type of gastroesophageal cancer.

January 7, 2026

2 min read

Tristan Manalac